#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal carcinoma Small intestine neuroendocrine tumour Hypocalcaemia Duchenne muscular dystrophy gene carrier Chronic granulomatous disease Glomerulonephritis minimal lesion Cardiac amyloidosis Fabry's disease Basal cell naevus syndrome Anaplastic thyroid cancer Cystic fibrosis Bladder cancer Renal cell carcinoma Arrhythmia Cardiac sarcoidosis More trials…

    Learn about Rare Diseases

    Progressive supranuclear palsy – Life with Disease Marginal zone lymphoma – Life with Disease Progressive supranuclear palsy Langerhans cell sarcoma – Diagnostics Langerhans cell sarcoma – Life with Disease Glomerulonephritis membranoproliferative Hereditary angioedema – Diagnostics Waldenstrom’s macroglobulinaemia – Trials in Disease Osteosarcoma – Basic Information Haemophilia B without inhibitors – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ioflupane (123I) Ethanol (96 Per Cent) Keto-Leucine Calcium Remestemcel Lufepirsen Tecovirimat Garetosmab Ro7269162 Bemnifosbuvir Hemisulfate Nimotuzumab Tepotinib Pramipexole RNMB2 TIFCEMALIMAB Betibeglogene Autotemcel Human Coagulation Factor Viii Saruparib Neostigmine Methylsulfate Ofloxacin Phenazone More therapies…

    Learn about Your Condition

    Palpitations Systemic mastocytosis Atrial fibrillation Neurodevelopmental disorder Infection Breast cancer recurrent Plasma cell myeloma recurrent Open angle glaucoma Amnestic disorder Oesophageal achalasia Death neonatal Malignant mast cell neoplasm Seasonal allergy Adenocarcinoma Corticobasal degeneration More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Prive Jean Mermoz

Hopital Prive Jean Mermoz

55 Avenue Jean Mermoz, Lyon, 69008, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Cisplatin
    Belgium Estonia France Germany Italy Latvia +2

  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study Comparing Regorafenib and Regorafenib-Irinotecan Combination for Patients with Metastatic Colorectal Cancer After Standard Treatments Have Failed

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Irinotecan
    • Regorafenib
    France

  • Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Fulvestrant
    • Inavolisib
    • Palbociclib
    Belgium France Germany Greece Hungary Italy +3

  • Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    Investigated Drugs:
    • Mitomycin
    • Capecitabine
    • Cisplatin
    France

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Giredestrant
    • Anastrozole
    Belgium France Germany Hungary Italy Poland +2

  • Study of Ezurpimtrostat with Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Gns561
    • Atezolizumab
    • Bevacizumab
    France

  • Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capivasertib
    • Abemaciclib
    • Fulvestrant
    Belgium Denmark France Germany Italy Poland +2

  • Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Olaparib
    • Bevacizumab
    Belgium Czechia France Germany Hungary Italy +2
Previous Page
1 … 7 8 9 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!